関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | tert-Butyl piperazine-1-carboxylate | HCID 143452 | — |
| 反応物 | 5-(Benzyloxy)-2-chloropyridine | HCID 10013717 | — |
| 試薬 | Sodium t-butoxide | HCID 23676156 | — |
| 触媒 | Binap, (A+-)- | HCID 634876 | — |
| 触媒 | (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one; palladium | HCID 6505921 | — |
| 溶媒 | Toluene | HCID 1140 | — |
| 生成物 | Tert-butyl 4-(5-(benzyloxy)pyridin-2-YL)piperazine-1-carboxylate | HCID 22221503 | 68.75% |
反応手順
BIS(DIBENZYLIDENEACETONE)PALLADIUM (0.055 g, 0.10 mmol) was added to tert- butyl piperazine-1-carboxylate (1.952 g, 10.48 mmol), 5-(benzyloxy)-2-chloropyridine (2.093 g, 9.53 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.059 g, 0.10 mmol) and sodium 2-methylpropan-2-olate (1.282 g, 13.34 mmol) in toluene (30 mL) at 20ºC under nitrogen. The resulting solution was stirred at 80 °C for 16 hours then cooled to room temperature. The reaction mixture was filtered through celite, filtrate partitioned between ethyl acetate (100 mL) and water (100 mL). The organic phase was dried (Na2SO4), filtered and evaporated to give a brown gum. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford tert-butyl 4-(5-(benzyloxy)pyridin-2-yl)piperazine-1-carboxylate (2.420 g, 68.7 %) as a yellow solid.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-8fcffc24262340ad8745959198669390 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|